EUVIMEDEUVIMED entdecken
EvaluationsstudieMultizentrische Studie

Intravenous antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention

Angelo Silverio, Michele Bellino, Fernando Scudiero, Tiziana Attisano, Cesare Baldi, Angelo Catalano, Mario Centore, Arturo Cesaro, Marco Di Maio, Luca Esposito, Giovanni Granata, Francesco Maiellaro und 8 weitere

Journal of Thrombosis and Thrombolysis · 2024

DOI: 10.1007/s11239-024-02970-7 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift Journal of Thrombosis and Thrombolysis, 2024. Verfasst von Angelo Silverio und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Surgery and Dentistry, University of Salerno, Via Salvador Allende, 43, 84081, Baronissi, Salerno, Italy. asilverio@unisa.it. Hauptthemen laut MEDLINE: Adenosine Monophosphate, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, ST Elevation Myocardial Infarction. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The use of intravenous antiplatelet therapy during primary percutaneous coronary intervention (PPCI) is not fully standardized. The aim is to evaluate the effectiveness and safety of periprocedural intravenous administration of cangrelor or tirofiban in a contemporary ST-segment elevation myocardial infarction (STEMI) population undergoing PPCI. This was a multicenter prospective cohort study including consecutive STEMI patients who received cangrelor or tirofiban during PPCI at seven Italian centers. The primary effectiveness measure was the angiographic evidence of thrombolysis in myocardial infarction (TIMI) flow < 3 after PPCI. The primary safety outcome was the in-hospital occurrence of BARC (Bleeding Academic Research Consortium) 2-5 bleedings. The study included 627 patients (median age 63 years, 79% males): 312 received cangrelor, 315 tirofiban. The percentage of history of bleeding, pulmonary edema and cardiogenic shock at admission was comparable between groups. Patients receiving cangrelor had lower ischemia time compared to tirofiban. TIMI flow before PPCI and TIMI thrombus grade were comparable between groups. At propensity score-weighted regression analysis, the risk of TIMI flow < 3 was significantly lower in patients treated with cangrelor compared to tirofiban (adjusted OR: 0.40; 95% CI: 0.30-0.53). The risk of BARC 2-5 bleeding was comparable between groups (adjusted OR:1.35; 95% CI: 0.92-1.98). These results were consistent across multiple prespecified subgroups, including subjects stratified for different total ischemia time, with no statistical interaction. In this real-world multicenter STEMI population, the use of cangrelor was associated with improved myocardial perfusion assessed by coronary angiography after PPCI without increasing clinically-relevant bleedings compared to tirofiban.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenosine MonophosphatePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsST Elevation Myocardial InfarctionTirofibanAgedFemaleHumansMaleMiddle AgedAdministration, IntravenousHemorrhageItalyProspective StudiesTreatment Outcome

Stichwörter der Autor:innen

BleedingsCangrelorOutcomesTIMITirofiban

Substanzen

Adenosine MonophosphatecangrelorPlatelet Aggregation InhibitorsTirofiban

Autor:innen und Institutionen

  • Department of Medicine, Surgery and Dentistry, University of Salerno, Via Salvador Allende, 43, 84081, Baronissi, Salerno, Italy. asilverio@unisa.it.
  • Department of Medicine, Surgery and Dentistry, University of Salerno, Via Salvador Allende, 43, 84081, Baronissi, Salerno, Italy.
  • Cardiology Unit, Medical Sciences Departement, ASST Bergamo Est, Seriate, Bergamo, Italy.
  • Interventional Cardiology Unit, University Hospital San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy.
  • Cardiology Unit, Hospital Maria SS. Addolorata, Eboli, Italy.
  • Department of Translational Medical Sciences, University of Campania 'Luigi Vanvitelli', Naples, Italy.

Zitieren

APA

Silverio, A., Bellino, M., Scudiero, F., Attisano, T., Baldi, C., Catalano, A., Centore, M., Cesaro, A., Di Maio, M., Esposito, L., Granata, G., Maiellaro, F., Muraca, I., Musumeci, G., Parodi, G., Personeni, D., Valenti, R., Vecchione, C., Calabrò, P., & Galasso, G. (2024). Intravenous antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis. https://doi.org/10.1007/s11239-024-02970-7

Vancouver

Silverio A, Bellino M, Scudiero F, Attisano T, Baldi C, Catalano A, et al. Intravenous antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis. 2024. doi:10.1007/s11239-024-02970-7

BibTeX
@article{Silverio2024,
  author = {Silverio, Angelo and Bellino, Michele and Scudiero, Fernando and Attisano, Tiziana and Baldi, Cesare and Catalano, Angelo and Centore, Mario and Cesaro, Arturo and Di Maio, Marco and Esposito, Luca and Granata, Giovanni and Maiellaro, Francesco and Muraca, Iacopo and Musumeci, Giuseppe and Parodi, Guido and Personeni, Davide and Valenti, Renato and Vecchione, Carmine and Calabrò, Paolo and Galasso, Gennaro},
  title = {Intravenous antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention},
  journal = {Journal of Thrombosis and Thrombolysis},
  year = {2024},
  doi = {10.1007/s11239-024-02970-7}
}
Kostenlos starten →